Sponsor & Developer Portfolio
Valneva
Clinical development pipeline, platform architecture, and registered trial tracking for Valneva vaccine candidates.
5
Candidates
3
Target Diseases
5
Linked Studies
Development Phase Distribution
Discontinued / Inactive: 2 Approved / Licensed: 1 Approved / Restricted: 1 Phase 3 Clinical Trial: 1
Platform Technologies
Biological (unspecified platform): 3 Live attenuated: 1 See FDA product page / label: 1
Target Pathogens & Indications
COVID-19 Chikungunya Japanese encephalitis
Vaccine Pipeline Candidates (5)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Approved / Licensed
ixchiq
Ixchiq (VLA1553 / Chikungunya live-attenuated vaccine)
Target: Chikungunya
Platform: Live attenuated
Key Milestone: Post-marketing safety surveillance; adolescent trial data readout
Approved / Restricted
fda-ixchiq
IXCHIQ
Target: Chikungunya
Platform: See FDA product page / label
Key Milestone: US-licensed — see product label / ACIP for use; further supplements may expand indication
Discontinued / Inactive
ctgov-ixiaro-valneva-austria-gmbh
IXIARO
Target: Japanese encephalitis
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2012-12 (registry estimate)
Discontinued / Inactive
ctgov-vla2001-valneva-austria-gmbh
VLA2001
Target: COVID-19
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2023-07-31 (registry estimate)
Phase 3 Clinical Trial
ctgov-vla1553-valneva-austria-gmbh
VLA1553
Target: Chikungunya
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2024-08-27 (registry estimate)
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.